Chronic cyclosporine nephropathy: The Achilles' heel of immunosuppressive therapy

Kidney International

Volumn 50, Issue 4, 1996, Pages 1089-1100

  Bennett, William M ^a,b   Demattos, Angelo ^a   Meyer, Mary M ^a   Andoh, Takeshi ^a   Barry, John M ^a  

^a Oregon Health Sciences University ^*

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN;

HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW;

EID: 0029806297     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1996.415     Document Type: Article

References (152)

1. TERASAKI PI, PARK MS, DANOVITCH GM: Histocompatibility testing, crossmatching, and allocation of cadaveric kidney transplants, in Handbook of Kidney Transplantation, edited by DANOVITCH GM, Boston, Little, Brown and Co., 1992, pp 43-66
2. DUNN J, GOLDEN D, VAN BUREN CT, LEWIS RM, LAWEN J. KAHAN BD: Causes of graft loss beyond two years in the cyclosporine era. Transplantation 49:349-353, 1990
3. BENNETT WM: The nephrotoxicity of immunosuppressive drugs. Clin Nephrol 43:S3-S7, 1995
4. TERASAKI PI, CECKA JM, CHO Y: Overview, in Clinical Transplants 1990, edited by TERASAKI PI, Los Angeles, UCLA Tissue Typing Laboratory, 1990
5. OPELZ G, SCHWARZ V, ENGELMANN A, BACK D, WILK M, KEPPEL E: Long-term impact of HLA matching on kidney graft survival in cyclosporine-treated recipients. Transplant Proc 23:373-375, 1991
6. MODENA FM, HOSTETTER TH, SALAHUDEEN AK, NAJARIAN JS, MATAS AJ, ROSENBERG ME: Progression of kidney disease in chronic-renal transplant rejection. Transplantation 52:239-244, 1991
7. REMUZZI G, PERICO N: Cyclosporine-induced renal dysfunction in experimental animals and humans. Kidney Int 48(Suppl 52):S70-S74, 1995
8. ENGLISH J, EVAN A, HOUGHTON DC, BENNETT WM: Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 44:135-141, 1987
9. SKORECKI KL, RUTLEDGE WP, SCHRIER RW: Acute cyclosporine nephrotoxicity - Prototype for a renal membrane signalling disorder. Kidney Int 42:1-10, 1992
10. PERICO N, RUGGENENTI P, GASPARI F, MOSCONI L, BENIGNI A, AMUCHASTEGUI CS, GASPARINI F, REMUZZI G: Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation. Transplantation 54:56-60, 1992
11. 2 receptor antagonists on cyclosporin A renal vasoconstriction. Am J Physiol 267:F443-F449, 1994
12. BOBADILLA NA, TAPIA E, FRANCO M, LOPEZ P, MENDOZA S, GARCIA-TORRES R, ALVARADO JA, HERRERA-ACOSTA J: Role of nitric oxide in renal hemodynamic abnormalities of cyclosporin nephrotoxicity. Kidney Int 46:773-779, 1994
13. 2+. Circ Res 74:477-484, 1994
14. BUNCHMAN TE, BROOKSHIRE CA: Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells. J Clin Invest 88:310-314, 1991
15. CURTIS JJ, LUKE RG, DUBOVSKY E, DIETHELM AG, WHELCHEL JD, JONES P: Cyclosporin in therapeutic doses increases renal allograft vascular resistance. Lancet 2:477-479, 1986
16. MIHATSCH MJ, RYFFEL B, GUDAT F: The differential diagnosis between rejection and cyclosporine toxicity. Kidney Int 48(Suppl 52):S63-S69, 1995
17. MIHATSCH MJ, STEINER K, ABEYWICKRAMA KH, LANDMANN J, THIEL G: Risk factors for the development of chronic cyclosporine-nephrotoxicity. Clin Nephrol 29:165-175, 1988
18. LEWIS RM: Long-term use of cyclosporine A does not adversely impact on clinical outcomes following renal transplantation. Kidney Int 48(Suppl 52):S75-S78, 1995
19. BRENNER BM, COHEN RA, MILFORD EL: In renal transplantation, one size may not fit all. J Am Soc Nephrol 3:162-169, 1992
20. WOLFE JA, MCCANN RL, SANFILIPPO F: Cyclosporine-associated microangiopathy in renal transplantation: a severe but potentially reversible form of early graft injury. Transplantation 41:541-544, 1986
21. VAN BUREN D, VAN BUREN CT, FLECHNER SM, MADDOX AM, VERANI R, KAHAN BD: De novo hemolytic uremic syndrome in renal transplant recipients immunosuppressed with cyclosporine. Surgery 98:54-62, 1985
22. MYERS BD, ROSS J, NEWTON L, LUETSCHER J, PERLROTH M: Cyclosporine-associated chronic nephropathy. N Engl J Med 311: 699-705, 1984
23. MYERS BD, SIBLEY R, NEWTON L, TOMLANOVICH SJ, BOSHKOS C, STINSON E, LUETSCHER JA, WHITNEY DJ, KRASNY D, COPLON NS, PERLROTH MG: The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 33:590-600, 1988
24. MYERS BD, NEWTON L, BOSHKOS C, MACOVIAK JA, FRIST WH, DERBY GC, PERLROTH MG, SIBLEY RK: Chronic injury of human renal microvessels with low-dose cyclosporine therapy. Transplantation 46:694-703, 1988
25. MYERS BD, NEWTON L: Cyclosporine-induced chronic nephropathy: An obliterative microvascular renal injury. J Am Soc Nephrol 2:S45-S52, 1991
26. ZIETSE R, BALK AH, VAN DER DORPEI. MA, MEETER K, BOS E, WEIMAR W: Time course of the decline in renal function in cyclosporine-treated heart transplant recipients. Am J Nephrol 14:1-5. 1994
27. GREENBERG A, THOMPSON ME, GRIFFITH BJ, HARDESTY RL. KORMOS RL, EL-SHAHAWY MA, JANOSKY JE, PUSCHETT JB: Cyclosporine nephrotoxicity in cardiac allograft patients - A seven-year follow-up. Transplantation 50:589-593, 1990
28. GREENBERG A, EGEL JW, THOMPSON ME, HARDESTY RL, GRIFFITH BP, BAHNSON HT, BERNSEIN RL, HASTILLO A, HESS ML, PUSCHETT JB: Early and late forms of cyclosporine nephrotoxicity: Studies in cardiac transplant recipients. Am J Kidney Dis 9:12-22, 1987
29. FALKENHAIN ME, COSIO FG: Cyclosporine (CsA) causes progressive glomerular sclerosis (GS) and arteriolar hyalinosis (AH) in kidneys of heart (HTx) and liver (LTx) transplant recipients. (abstract) J Am Soc Nephrol 5: 1003, 1994
30. LEWIS RM, VAN BUREN CT, RADOVANCEVIC B, FRAZIFR OH, JANNEY RP, POWERS PL, GOLDEN DL, GIANNAKIS JG, MACRIS MP. KERMAN RH, KAHAN BD: Impact of long-term cyclosporine immunosuppressive therapy on native kidneys versus renal allografts: Serial renal function in heart and kidney transplant recipients. J Heart Lung Transplant 10:63-70, 1991
31. GONWA TA, MAI ML, PILCHER J, JOHNSON C, PIERSON S, CAPEHART JE, ALIVIZATOS PA: Stability of long-term renal function in heart transplant patients treated with induction therapy and low-dose cyclosporine. J Heart Lung Transplant 11:926-928, 1992
32. BERTANI T, FERRAZZI P, SCHIEPPATI A, RUGGENENTI P, GAMBA A, PARENZAN L, MECCA G, PERICO N, IMBERTI O, REMUZZI A, REMUZZI G: Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients. Kidney Int 40:243-250, 1991
33. RUGGENENTI P, PERICO N, AMUCHASTEGUI CS, FERRAZZI P, MAMPRIN F, REMUZZI G: Following an initial decline, glomerular filtration rate stabilizes in heart transplant patients on chronic cyclosporine. Am J Kidney Dis 24:549-553, 1994
34. ZALTZMAN JS, PEI Y, MAURER J, PATTERSON A, CATTRAN DC: Cyclosporine nephrotoxicity in lung transplant recipients. Transplantation 54:875-878, 1992
35. PATTISON JM, PETERSEN J, KUO P, VALANTINE V, ROBBINS RC, THEODORE J: The incidence of renal failure in one hundred consecutive heart-lung transplant recipients. Am J Kidney Dis 26:643-648, 1995
36. JACOBSON SH, JAREMKO G, DURAJ FF, WILCZEK HE: Renal fibrosis in cyclosporine A treated renal allograft recipients: morphological findings in relation to renal hemodynamics. Nephron (in press)
37. RUIZ P, KOLBECK PC, SCROGGS MW, SANFILIPPO F: Associations between cyclosporine therapy and interstitial fibrosis in renal allograft biopsies. Transplantation 45:91-95, 1988
38. KLINTMALM G, SUNDELIN B, BOHMAN SO, WILCZEK H: Interstitial fibrosis in renal allografts after 12 to 46 months of cyclosporin treatment: Beneficial effect of low doses in early post-transplantation period. Lancet 2:950-954, 1984
39. SOMMER BG, INNES JT, WHITEHURST RM, SHARMA HM, FERGUSON RM: Cyclosporine-associated renal arteriopathy resulting in loss of allograft function. Am J Surg 149:756-764, 1985
40. BURKE JFJ, PIRSCH JD, RAMOS EL, SALOMON DR, STABLEIN DM, VAN BUREN DH, WEST JC: Long-term efficacy and safety of cyclosporine in renal-transplant recipients. N Engl J Med 331:358-363, 1994
41. SUMRANI N, DELANEY V, DING Z, BUTT K, HONG; J: HLA-identical renal transplants: Impact of cyclosporine on intermediate-term survival and renal function. Am J Kidney Dis 16:417-422, 1990
42. LEWIS R, PODBIELSKI J, MUNSELL M, KATZ S, VAN BUREN C, KERMAN R, KAHAN BD: Stability of renal allograft glomerular filtration rate in the cyclosporine era: 2-year follow-up. Transplant Proc 26:2619-2621, 1994
43. SLOMOWITZ LA, WILKINSON A, HAWKINS R, DANOVITCH G: Evaluation of kidney function in renal transplant patients receiving long-term cyclosporine. Am J Kidney Dis 15:530-534, 1990
44. MOURAD G, VELA C, RIBSTEIN J, MIMRAN A: Chronic cyclosporine nephrotoxicity is reversible in renal transplant recipients. (abstract) Nephrol Dial Transplant 8:1045, 1993
45. MOROZUMI K, THIEL G, ALBERT FW, BANFI G, GUDAT F, MIHATSCH MJ: Studies on morphological outcome of cyclosporine-associated arteriolopathy after discontinuation of cyclosporine in renal allografts. Clin Nephrol 38:1-8, 1992
46. SCHERRER U, VISSING SF, MORGAN BJ, ROLLINS JA, TINDALL RSA, RING S, HANSON P, MOHANTY PK, VICTOR RG: Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med 323:693-699, 1990
47. MARK AL: Cyclosporine, sympathetic activity, and hypertension. N Engl J Med 323:748-750, 1990
48. ELZINGA LW, ROSEN S, LINDSLEY J, BURDMANN EA, BENNETT WM: The role of the sympathetic nervous system in a model of chronic cyclosporine nephropathy. (abstract) J Am Soc Nephrol 3:722, 1992
49. PALESTINE AG, AUSTIN HAI, BALOW JE, ANTONOVYCH TT, SABNIS SG, PREUSS HG, NUSSENBLATT RB: Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med 314:1293-1298, 1986
50. AUSTIN HAI, PALESTINE AG, SABNIS SG, BALOW JE, PREUSS HG, NUSSENBLATT RB, ANTONOVYCH TT: Evolution of ciclosporin nephrotoxicity in patients treated for autoimmune uveitis. Am J Nephrol 9:392-402, 1989
51. DERAY G, BENHMIDA M, LE HOANG P, MAKSUD P, AUPETIT B, BAUMELOU A, JACOBS C: Renal function and blood pressure in patients receiving long-term, low-dose cyclosporine therapy for idiopathic autoimmune uveitis. Ann Intern Med 117:578-583, 1992
52. ANDERSEN CB, LARSEN S, ELMGREEN J, TVEDE N, ANDERSEN V: Cyclosporine-induced renal morphologic and immunohistologic changes in patients with chronic uveitis. APMIS 99:576-582, 1991
53. FELDT-RASMUSSEN B, JENSEN T, DIEPERINK H, MANDRUP-POULSEN T, NERUP J, BENDTZEN K, ANDERSEN V, KEMP E, LEYSSAC PP: Nephrotoxicity of cyclosporin A in patients with newly diagnosed type 1 diabetes mellitus. Diabetic Med 7:429-433, 1990
54. ASSAN R, TIMSIT J, FEUTREN G, BOUGNERES P, CZERNICHOW P, HANNEDOUCHE T, BOTTARD C, NOEL LH, MIHATSCH MJ, BACH JF: The kidney in cyclosporin A-treated diabetic patients: A long-term clinicopathological study. Clin Nephrol 41:41-49, 1994
55. MIHATSCH MJ, HELMCHEN U, CASANOVA P, HABIB R, LARSEN S, MAGIL A, NOEL LH, RAPOLA J, ULRICH J, WALLACE AC: Kidney biopsy findings in cyclosporine-treatcd patients with insulin-dependent diabetes mellitus. Klin Wochenschr 69:354-359, 1991
56. FEUTREN G, MIHATSCH MJ: Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. N Engl J Med 326:1654-1660, 1992
57. FIORETTO P, STEFFES MW, MIHATSCH MJ, STROM EH, SUTHERLAND DER, MAUER M: Cyclosporine associated lesions in native kidneys of diabetic pancreas transplant recipients. Kidney Int 48:489-495, 1995
58. POWLES AV, COOK T, HULME B, BAKER BS, LEWIS HM, THOMAS E, VALDIMARSSON H, FRY L: Renal function and biopsy findings after 5 years' treatment with low-dose cyclosporin for psoriasis. Br J Dermatol 128:159-165, 1993
59. SVARSTAD E, HELLAND S, MORKEN T, BOSTAD L, MYKING A, IVERSEN BM. OFSTAD J: Renal effects of maintenance low-dose cyclosporin A treatment in psoriasis. Nephrol Dial Transplant 9:1462-1467, 1994
60. BAGNIS C, DERAY G, KADRI A, LE HOANG P, MAKSUD P, JACOBS C: Ciclosporine (CsA) nephrotoxicity in patients with idiopathic uveitis: A live years follow-up. (abstract) J Am Soc Nephrol 5:388, 1994
61. PEI Y, SCHOLEY JW, KATZ A, SCHACHTER R, MURPHY GF, CATTRAN D: Chronic nephrotoxicity in psoriatic patients treated with low-dose cyclosporine. Am J Kidney Dis 23:528-536, 1994
62. MESSANA JM, JOHNSON KJ, MIHATSCH MJ: Renal structure and function effects after low dose cyclosporine in psoriasis patients: A preliminary report. Clin Nephrol 43:150-153, 1995
63. ZACHARIAE H, HANSEN HE, KRAGBALLE K, OLSEN S: Morphologicrenal changes during cyclosporine treatment of psoriasis. Studies on pretreatment and posttreatment kidney biopsy specimens. J Am Acad Dermatol 26:415-419, 1992
64. ZACHARIAE H, OLSEN TS: Efficacy of cyclosporin A (CyA) in psoriasis: An overview of dose/response, indications, contraindications and side-effects, Clin Nephrol 43:154-158, 1995
65. YOUNO EW, ELLIS CN, MESSANA JM, JOHNSON KJ, LEICHTMAN AB, MIHATSCH MJ, HAMILTON TA, GROISSER DS, FRADIN MS, VOORHEES JJ: A prospective study of renal structure and function in psoriasis patients treated with cyclosporin. Kidney Int 46:1216-1222, 1994
66. EDWARDS BD, CHALMERS RJG, O'DRISCOLL JB, MITCHELL DM, SMITH RJ, LAWSON RS, TESTA HJ, BALLARDIE FW: Angiotensin II as a risk factor for cyclosporin nephrotoxicity in patients with psoriasis. Clin Nephrol 41:350-356, 1994
67. SOWDEN JM, BERTH-JONES J, ROSS JS, MOTLEY RJ, MARKS R, FINLAY AY, SALEK MS, GRAHAM-BROWN RAC, ALLEN BR, CAMP RDR: Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 338:137-140, 1991
68. THE MULTIPLE SCLEROSIS STUDY GROUP: Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: A randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol 27:591-605, 1990
69. SUND S, FORRE O, BERG KJ, KVIEN TK, HOVIG T: Morphological and functional renal effects of long-term low-dose cyclosporin A treatment in patients with rheumatoid arthritis. Clin Nephrol 41:33-40, 1994
70. MIHATSCH MJ, HOVIG T, LEMOINE R, ALEXOPOULOU I, FORRE O, MIESCHER P, FAVRE H, LUDWIN D, TUGWELL P, BJERKHOEL N, VON GRAFFENRIED B, FEUTREN G: Renal morphology after cyclosporin A therapy in rheumatoid arthritis patients. Br J Rheumatol 32:65-71, 1993
71. MADHOK R, TORLEY HI, CAPELL HA: A study of the longterm efficacy and toxicity of cyclosporine A in rheumatoid arthritis. J Rheumatol 18:1485-1489, 1991
72. AHERN MJ, HARRISON W, HOLLINGSWORTH P, BRADLEY J, LAING B. BAYLISS C: A randomised double-blind trial of cyclosporin and azathioprine in refractory rheumatoid arthritis. Aust NZ J Med 21:844-849, 1991
73. LANDEWE RBM, GOEI THE HS, VAN RIJTHOVEN AWAM, BREEDVELD FC, DIJKMANS BAC: A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis. Arthritis Rheum 37:637-643, 1994
74. LUDWIN D, ALEXOPOULOU I: Cyclosporin A nephropathy in patients with rheumatoid arthritis. Br J Rheumatol 32:60-64, 1993
75. COHEN DJ, APPEL GB: Cyclosporine: Nephrotoxic effects and guidelines for safe use in patients with rheumatoid arthritis. Semin Arthritis Rheum 21:43-48, 1992
76. LANDEWE RBM, DIJKMANS BAC, VAN DER WOUDE FJ, BREEDVELD FC, MIHATSCH MJ, BRUIJN JA: Longterm low dose cyclosporine in patients with rheumatoid arthritis: Renal function loss without structural nephropathy. J Rheumatol 23:61-64, 1996
77. CLEMENTS PJ, LACHENBRUCH PA, STERZ M, DANOVITCH G, HAWKINS R, IPPOLITI A, PAULUS HE: Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients. Arthritis Rheum 36:75-83, 1993
78. WIESNER RH, LUDWIG J, LINDOR KD, JORGENSEN RA, BALDUS WP, HOMBURGER HA, DICKSON ER: A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N Engl J Med 322:1419-1424, 1990
79. LOMBARD M, PORTMANN B, NEUBERGER J, WILLIAMS R, TYGSTRUP N, RANEK L, RING-LARSEN H, RODES J, NAVASA M, TREPO C, PAPE G, SCHOU G, BADSBERG JH, ANDERSEN PK: Cyclosporin A treatment in primary biliary cirrhosis: Results of a long-term placebo controlled trial. Gastroenterology 104:519-526, 1993
80. KOLKIN S, NAHMAN NSJ, MENDELL JR: Chronic nephrotoxicity complicating cyclosporine treatment of chronic inflammatory demyclinating polyradiculoneuropathy. Neurology 37:147-149, 1987
81. HANNEDOUCHE TP, DELGADO AG, GNIONSAHE AD, BOTTARD C, NOEL LH, GRUNFELD JP: Nephrotoxicity of cyclosporine in autoimmune diseases. Adv Nephrol 19:169-186, 1990
82. TINDALL RSA, ROLLINS JA, PHILLIPS JT, GREENLEE RG, WELLS L, BELENDIUK G: Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 316:719-724, 1987
83. PLATZ KP, MUELLER AR, BLUMHARDT G, BACHMANN S, BECHSTEIN WO, KAHL A, NEUHAUS P: Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 58:170-178, 1994
84. WHEATLEY HC, DATZMAN M, WILLIAMS JW, MILES DE, HATCH FE: Long-term effects of cyclosporine on renal function in liver transplant recipients. Transplantation 43:641-647, 1987
85. DISCHE FE, NEUBERGER J, KEATING J, PARSONS V, CALNE RY, WILLIAMS R: Kidney pathology in liver allograft recipients after long-term treatment with cyclosporin A. Lab Invest 58:395-402, 1988
86. MONSOUR HPJ, WOOD RP, DYER CH, GALATI JS, OZAKI CF, CLARK JH: Renal insufficiency and hypertension as long-term complications in liver transplantation. Semin Liver Dis 15:123-132, 1995
87. MCCAULEY J, BRONSTHER O, FUNG J, TODO S, STARZL TE: Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet 2:1516, 1989
88. GONWA TA, MORRIS CA, GOLDSTEIN RM, HUSBERG BS, KLINTMALM GB: Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome - Experience in 300 patients. Transplantation 51:428-430, 1991
89. DIETERLE A, GRATWOHL A, NIZZE H, HUSER B, MIHATSCH MJ, THIEL G, TICHELLI A, SIGNER E, NISSEN C, SPECK B: Chronic cyclosporine-associated nephrotoxicity in bone marrow transplant patients. Transplantation 49:1093-1100, 1990
90. NIZZE H, MIHATSCH MJ, ZOLLINGER HU, BROCHERIOU C, GOKEL JM, HENRY K, SLOANE JP, STOVIN PG: Cyclosporine-associated nephropathy in patients with heart and bone marrow transplants. Clin Nephrol 30:248-260, 1988
91. DELANEY MP, DUKES DC, EDMUNDS ME: Cyclosporin A in refractory idiopathic nephrotic syndrome: 5 years clinical experience. Postgrad Med J 70:891-894, 1994
92. HULTON SA, JADRESIC L, SHAH V, TROMPETER RS, DILLON MJ, BARRATT TM: Effect of cyclosporin A on glomerular filtration rate in children with minimal change nephrotic syndrome. Pediatr Nephrol 8:404-407, 1994
93. HABIB R, NIAUDET P: Comparison between pre- and posttreatment renal biopsies in children receiving ciclosporine for idiopathic nephrosis. Clin Nephrol 42:141-146, 1994
94. NIAUDET P, HABIB R: Cyclosporine in the treatment of idiopathic nephrosis. J Am Soc Nephrol 5:1049-1056, 1994
95. MEYRIER A, NOEL LH, AURICHE P, CALLARD P, BRONEER D: Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Kidney Int 45:1446-1456, 1994
96. PONTICELLI C: Focal segmental glomerular sclerosis. To treat or not to treat? 1. It is worthwhile to give the adult patient with nephrotic syndrome the benefit of an adequate therapeutic trial? Nephrol Dial Transplant 10:2351-2354, 1995
97. MEYRIER A: Focal segmental glomerulosclerosis: To treat or not to treat? 2. Focal and segmental glomerulosclerosis is not a disease, but an untreatable lesion of unknown pathophysiology. Its treatment must not be uselessly hazardous. Nephrol Dial Transplant 10:2355-2359, 1995
98. CATTRAN DC, GREENWOOD C, RITCHIE S, BERNSTEIN K, CHURCHILL DN, CLARK WF, MORRIN PA, LAVOIE S: A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Kidney Int 47:1130-1135, 1995
99. FAVRE H, MIESCHER PA, HUANG YP, CHATELANAT F, MIHATSCH MJ: Ciclosporin in the treatment of lupus nephritis. Am J Nephrol 9:57-60, 1989
100. LAFAYETTE RA, MAYER G, MEYER TW: The effects of blood pressure reduction on cyclosporine nephrotoxicity in the rat. J Am Soc Nephrol 3:1892-1899, 1993
101. STAHL RAK, ADLER S, BAKER PJ, JOHNSON RJ, CHEN YP, PRITZL P, COUSER WG: Cyclosporin A inhibits prostaglandin E2 formation by rat mesangial cells in culture. Kidney Int 35:1161-1167, 1989
102. LANESE DM, CONGER JD: Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest 91:2144-2149, 1993
103. AUCH-SCHWELK W, DUSKE E, HINK U, BETZ M, UNKELBACH M, FLECK E: Vasomotor responses in cyclosporin A-treated rats after chronic angiotensin blockade. Hypertension 23:832-837, 1994
104. MARUMO T, NAKAKI T, HISHIKAWA K, SUZUKI H, KATO R, SARUTA T: Cyclosporin A inhibits nitric oxide synthase induction in vascular smooth muscle cells. Hypertension 25:764-768, 1995
105. KON V, HUNLEY TE, FOGO A: Combined antagonism of endothelin A/B receptors links endothelin to vasoconstriction whereas angiotensin II effects fibrosis. Studies in chronic cyclosporine nephrotoxicity in rats. Transplantation 60:89-95, 1995
106. BOKEMEYER D, KRAMER HJ, MEYER-LEHNERT H: Atrial natriuretic peptide blunts the cellular effects of cyclosporine in smooth muscle. Hypertension 21:166-172, 1993
107. TAKENAKA T, HASHIMOTO Y, EPSTEIN M: Diminished acetylcholine-induced vasodilation in renal microvessels of cyclosporine-treated rats. J Am Soc Nephrol 3:42-50, 1992
108. SHEHATA M, EL NAHAS AM, BARKWORTH E, COPE GH, RAFTERY AT: Increased platelet-derived growth factor in the kidneys of cyclosporin-treated rats. Kidney Int 46:726-732, 1994
109. ROSSI NF, CHURCHILL PC, MCDONALD FD, ELLIS VR: Mechanism of cyclosporin A-induced renal vasoconstriction in the rat. J Pharmacol Exp Ther 250:896-901, 1989
110. GALLEGO MJ, LOPEZ FARRE A, RIESCO A, MONTON M, GRANDES SM, BARAT A, HERNANDO L, CASADO S, CARAMELO CA: Blockade of endothelium-dependent responses in conscious rats by cyclosporin A: Effect of L-arginine. Am J Physiol 264:H708-H714, 1993
111. DE NICOLA L, THOMSON SC, WEAD LM, BROWN MR, GABBAI FB: Arginine feeding modifies cyclosporine nephrotoxicity in rats. J Clin Invest 92:1859-1865, 1993
112. MARTIN M, NEUMANN D, HOFF T, RESCH K, DEWITT DL, GOPPELT-STRUEBE M: Interleukin-1-induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells. Kidney Int 45:150-158, 1994
113. LUSCHER TF, WENZEL RR: Endothelin in renal disease: Role of endothelin antagonists. Nephrol Dial Transplant 10:162-166, 1995
114. GHIGGERI GM, ALTIERI P, OLEGGINI R, SPADA F, GINEVRI F, PERFUMO F, GUSMANO R: Selective enhancement by cyclosporin A of collagen expression by mesangial cells "in culture." Eur J Pharmacol 270:195-201, 1994
115. WOLF G, NEILSON EG: Increases in levels of collagen types I and IV messenger ribonucleic acid in murine kidneys after treatment with ciclosporin. Nephron 60:87-91, 1992
116. ROSEN S, GREENFELD Z, BREZIS M: Chronic cyclosporine-induced nephropathy in the rat. A medullary ray and inner stripe injury. Transplantation 49:445-452, 1990
117. ELZINGA LW, ROSEN S, BENNETT WM: Dissociation of glomerular filtration rate from tubulointerstitial fibrosis in experimental chronic cyclosporine nephropathy: Role of sodium intake. J Am Soc Nephrol 4:214-221, 1993
118. FRANCESCHINI N, ALPERS CE, ANDOH TF, BURDMANN EA, BENNETT WM: Arteriolopathy persists after drug withdrawal in rats with chronic cyclosporine nephrotoxicity. (abstract) J Am Soc Nephrol 5:778, 1994
119. MASON J, MULLER-SCHWEINITZER E, DUPONT M, CASELLAS D, MIHATSCH M, MOORE L, KASKEL F: Cyclosporine and the reninangiotcnsin system. Kidney Int 39(Suppl 32):S28-S32, 1991
120. BURDMANN EA, ANDOH TF, NAST CC, EVAN A, CONNORS BA, COFFMAN TM, LINDSLEY J, BENNETT WM: Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. Am J Physiol 269:F491-F499, 1995
121. YOUNG BA, BURDMANN EA, JOHNSON RJ, ANDOH T, BENNETT WM, COUSER WG, ALPERS CE: Cyclosporine A induced arteriolopathv in a rat model of chronic cyclosporine nephropathy. Kidney Int 48:431-438, 1995
122. YOUNG BA, BURDMANN EA, JOHNSON RJ, ALPERS CE, GIACHEELI CM, ENG E, ANDOH T, BENNETT WM, COUSER WG, LINDSLEY J, DUYN J: Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity. Kidney Int 48:439-448, 1995
123. JACKSON NM, O'CONNOR RP, HUMES HD: Interactions of cyclosporine with renal proximal tubule cells and cellular membranes. Transplantation 46:109-114, 1988
124. ROGERS TS, ELZINGA L, BENNETT WM, KELLEY VE: Selective enhancement of thromboxane in macrophages and kidneys in cyclosporine-induced nephrotoxicity. Dietary protection by fish oil. Transplantation 45:153-156, 1988
125. WOLF G, NEILSON EG: Angiotensin II as a renal growth factor. J Am Soc Nephrol 3:1531-1540, 1993
126. MOORE LC, CASELLAS D, BEAUDOIN R, KUPFERMAN J, BEAUDOIN D, BIZGALIS A, KASKEL FJ: Dose-dependent renin recruitment by cyclosporines A and G in rat afferent arterioles (AA). (abstract) J Am Soc Nephrol 5:927, 1995
127. JACKSON NM, HSU CH, VISSCHER GE, VENKATACHALAM MA, HUMES HD: Alterations in renal structure and function in a rat model of cyclosporine nephrotoxicity. J Pharmacol Exp Ther 242: 749-756, 1987
128. TUFRO-MCREDDIE A, GOMEZ RA, NORLING LL, OMAR AA, MOORE LC, KASKEL FJ: Effect of CsA on the expression of renin and angiotensin type 1 receptor genes in the rat kidney. Kidney Int 43:615-622, 1993
129. JOHNSON RJ, ALPERS CE, YOSHIMURA A, LOMBARDI D, PRITZL P, FLOEGE J, SCHWARTZ SM: Renal injury from angiotensin II-mediated hypertension. Hypertension 19:464-474, 1992
130. MEISTER B, LIPPOLDT A, BUNNEMANN B, INAGAMI T, GANTEN D, FUXE K: Cellular expression of angiotensin type-1 receptor mRNA in the kidney. Kidney Int 44:331-336, 1993
131. GARDINER DS, WATSON MA, JUNOR BJR, BRIGGS JD, MORE IAR, LINDOP GBM: The effect of conversion from cyclosporin to azathioprine on renin-containing cells in renal allograft biopsies. Nephrol Dial Transplant 6:363-367, 1991
132. 1, and its receptor by cyclosporine in human T lymphocytes. Transplantation 60:718-723, 1995
133. KLTTELER M, NOBLE NA, BORDER WA: Transforming growth factor-β and the kidney. J Nephrol 8:143-147, 1995
134. SHIHAB FS, ANDOH TF, TANNER AM, NOBLE NA, FRANCESCHINI N, BENNETT WM: Role of Transforming growth factor-β1 in experimental chronic cyclosporine nephropathy. Kidney Int (in press)
135. SHEHATA M, COPE GH, JOHNSON TS, RAFTERY AT, EL NAHAS AM: Cyclosporine enhances the expression of TGF-β in the juxtaglomerular cells of the rat kidney. Kidney Int 48:1487-1496, 1995
136. KHANNA A, LI B, STENZEL KH, SUTHANTHIRAN M: Regulation of new DNA synthesis in mammalian cells by cyclosporine. Transplantation 57:577-582, 1994
137. KHANNA A, LI B, SEHAJPAL PK, SHARMA VK, SUTHANTHIRAN M: Mechanism of action of cyclosporine: A new hypothesis implicating transforming growth factor-β. Transplant Rev 9:41-48, 1995
138. ENGLISH JA, BURDMANN EA, ANDOH TF, STILLMAN I, FRANCESCHINI N, LINDSLEY J, ROSEN S, BENNETT WM: Effect of prednisone on experimental chronic cyclosporine nephrotoxicity. (abstract) Clin Res 42:94A, 1994
139. GRIFFTTHS EJ, HALESTRAP AP: Protection by cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts. J Mol Cell Cardiol 25:1461-1469, 1993
140. UCHINO H, ELMER E, UCHINO K, LINDVALL O, SIESJO BK: Cyclosporin A dramatically ameliorates CA1 hippocampal damage following transient forebrain ischaemia in the rat. Acta Physiol Scand 155:469-471, 1995
141. GARCIA DEL MORAL R, O'VALLE F, ANDUJAR M, AGUILAR M, LUCENA MA, LOPEZ-HIDALGO J, RAMIREZ C, MEDINA-CANO MT, AGUILAR D, GOMEZ-MORALES M: Relationship between P-glycoprotein expression and cyclosporin A in kidney. An imnunohistological and cell culture study. Am J Pathol 146:398-408, 1995
142. HIESSE C, NEYRAT N, DEGLISE-FAVRE A, LANTZ O, BENSADOUN H, BENOIT G, CHARPENTIER B, FRIES D: Randomized prospective trial of elective cyclosporine withdrawal from triple therapy at 6 months after cadaveric renal transplantation. Transplant Proc 23:987-989, 1991
143. PEDERSEN EB, HANSEN HE, KORNERUP HJ, MADSEN S, SORENSEN AW: Long-term graft survival after conversion from cyclosporin to azathioprine 1 year after renal transplantation. A prospective, randomized study from 1 to 6 years after transplantation. Nephrol Dial Transplant 8:250-254, 1993
144. HOLLANDER AAMJ, VAN SAASE JLCM, KOOTTE AMM, VAN DORP WT, VAN BOCKEL HJ, VAN ES LA, VAN DER WOUDE FJ: Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet 345:610-614, 1995
145. FERGUSON CJ, WILLIAMS JD, HILLIS AN, PARRY-JONES D, SALAMAN JR: Effects of the calcium channel blocker diltiazem on cyclosporin nephrotoxicity in renal transplant patients. Clin Transplant 6:391-398, 1992
146. PALMER BF, DAWIDSON I, SAGALOWSKY A, SANDOR Z, LU CY: Improved outcome of cadaveric renal transplantation due to calcium channel blockers. Transplantation 52:640-645, 1991
147. CHRYSOSTOMOU A, WALKER RG, RUSS GR, D'APICE AJF, KINCAIDSMITH P, MATHEW TH: Diltiazem in renal allograft recipients receiving cyclosporine. Transplantation 55:300-304, 1993
148. MCCULLOCH TA, HARPER R SJ, DONNELLY PK, MOORHOUSE J, BELL PRF, WALLS J, FEEHALLY J, FURNESS PN: Influence of nifedipine on interstitial fibrosis in renal transplant allografts treated with cyclosporin A. J Clin Puthol 47:839-842, 1994
149. RUGGENENTI P, PERICO N, MOSCONI L, GASPARI F, BENIGNI A, AMUCHASTEGUI CS, BRUZZI I, REMUZZI G: Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int 43:706-711, 1993
150. BANTLE JP, PALLER MS, BOUDREAU RJ, OLIVARI MT, FERRIS TF: Long-term effects of cyclosporine on renal function in organ transplant recipients. J Lab Clin Med 115:233-240, 1990
151. VAN BUREN DH, BURKE JF, LEWIS RM: Renal function in patients receiving long-term cyclosporine therapy. J Am Soc Nephrol 4:SI7-S22, 1994
152. SNIDER J, FRANCIS DMA, KINCAID-SMITH P, WALKER RG: Long-term graft survival and renal function in cyclosporin-treated renal allograft recipients: Lack of evidence of nephrotoxicity. Clin Transplant 7:25-27, 1993